300
Participants
Start Date
February 21, 2021
Primary Completion Date
September 30, 2024
Study Completion Date
December 31, 2024
HEPLISAV-B
This study is strictly observational. Administration of HEPLISAV-B, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
PPD Registry Office, Recruiting Nationwide, Wilmington
Lead Sponsor
PPD, Part of Thermo Fisher Scientific
INDUSTRY
Dynavax Technologies Corporation
INDUSTRY